Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Bilateral Nasal Polyposis (SINUS-24)
NCT02912468Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Dupilumab with Placebo (2 arms). Primary endpoints: Nasal Congestion/Obstruction Symptom Severity at 24 weeks, Nasal Polyp Score at 24 weeks and 1 more. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT02912468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912468.